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Interactions between cancer stem cells and their
niche govern metastatic colonization
Ilaria Malanchi1*, Albert Santamaria-Martı´nez1*, Evelyn Susanto1, Hong Peng1,2, Hans-Anton Lehr3, Jean-Francois Delaloye4
& Joerg Huelsken1
Metastatic growth in distant organs is the major cause of cancer
mortality. The development of metastasis is a multistage process
with several rate-limiting steps1.Althoughdisseminationof tumour
cells seems to be an early and frequent event2, the successful
initiation of metastatic growth, a process termed ‘metastatic
colonization’, is inefficient for many cancer types and is accomp-
lished only by a minority of cancer cells that reach distant sites3,4.
Prevalent target sites are characteristic of many tumour entities5,
suggesting that inadequate support by distant tissues contributes to
the inefficiency of themetastatic process. Here we show that a small
population of cancer stem cells is critical for metastatic coloniza-
tion, that is, the initial expansion of cancer cells at the secondary
site, and that stromal niche signals are crucial to this expansion
process. We find that periostin (POSTN), a component of the
extracellular matrix, is expressed by fibroblasts in the normal tissue
and in the stroma of the primary tumour. Infiltrating tumour cells
need to induce stromal POSTN expression in the secondary target
organ (in this case lung) to initiate colonization. POSTN is required
to allow cancer stem cell maintenance, and blocking its function
prevents metastasis. POSTN recruits Wnt ligands and thereby
increases Wnt signalling in cancer stem cells. We suggest that the
education of stromal cells by infiltrating tumour cells is an import-
ant step in metastatic colonization and that preventing de novo
niche formation may be a novel strategy for the treatment of
metastatic disease.
We aimed to explore limiting factors that determine metastatic
success using the MMTV-PyMT mouse breast cancer model, which
spontaneously metastasizes to the lungs6. We reasoned that the
recently identified cancer stem cells (CSCs, also called tumour-initiating
cells), a subset of cancer cells that allow long-term tumour growth and
are thought to be responsible for remissions7,8,might also be relevant to
the development of metastatic disease (Supplementary Fig. 1). We
measured the relative size of the population of CSCs from primary
MMTV-PyMT tumours and their pulmonary metastases using the
previously established markers CD90 and CD24, which label a subset
of the CD241CD29hi or CD241CD49fhi population used earlier to
isolate CSCs and normal mammary gland stem cells9–13 (Supplemen-
tary Fig. 2). This CSC subset accounts for 36 2.1% (s.d.) of all tumour
cells from both primary tumours and metastases (Fig. 1a). When
CD901CD241 CSCs or CD901CD241-depleted non-CSCs are sepa-
rately isolated from GFP1 tumours and directly introduced into mice
through tail vein injection (GFP, green fluorescent protein), only the
CSCpopulation is able to produce lungmetastases (Fig. 1b).Moreover,
CD901CD241 cells isolated subsequently frompulmonarymetastases
are again the only tumour cell population that efficiently initiates
secondary metastases (Fig. 1c). This is not due to differences in the
extravasation capabilities of CSCs and non-CSCs (Supplementary
Fig. 3).
In time course experiments, the relative size of the CSC population
changes drastically during metastatic colonization. When injecting
unfractionated tumour cells, the total number of tumour cells in the
lung declines rapidly within the first 7 d after seeding14 (Fig. 1d and
Supplementary Fig. 4). Notably, the relative amount of CSCs
transiently increases within the first and second weeks to more than
20%. This is due to selective expansion of the stem cell population as a
result of their proliferation rate increasing over sixfold relative to the
primary tumour in this early phase of metastatic colonization (as
measured by BrdU incorporation; Fig. 1e and Supplementary Fig. 5).
By contrast, non-CSCs show reduced proliferation 7 d after injection
and, notably, fail to generate CSCs (Fig. 1e and Supplementary Fig. 6).
Consequently, only CSCs are able to form metastatic colonies, and
non-CSCs remain as single cells (Fig. 1f). Together, this demonstrates
that selective expansion of CSCs is responsible for the initiation of
metastasis.
The number of injected CSCs evidently exceeds the number of
metastatic nodules, indicating that additional factors restrict successful
metastatic colonization. Stem cells are suspected to rely on signals
from their stromal environment, such as localized growth factors that
can affect stem cell maintenance and proliferation15–17. We identified
Postn as a stromal factor of normal stem cell niches and the metastatic
niche (Supplementary Methods). Postn encodes for periostin, which
becomes incorporated in the extracellular matrix18 and has a role in
bone, tooth and heart development and function19–21. Its expression is
downregulated in the adult except in niches in direct contact with
tissue-specific stem cells in mammary gland, bone, skin and intestine
(Fig. 2a and Supplementary Figs 7 and 8). In tumours, POSTN is
produced by stromal aSMA1VIM1 (aSMA also known as ACTA2)
fibroblasts according to RNA in situ hybridization, immunostaining
and quantitative PCR (Fig. 2b–h). Notably, POSTN expression is
induced in the lung stroma by infiltrating cancer cells (Fig. 2d), but
does not occur in the alveolar lung tissue of tumour-bearing but
metastasis-free animals (Supplementary Fig. 8). Human breast cancer
patients show inductionof stromal POSTNexpression in 75%of lymph
nodemetastases (Fig. 2i, j and Supplementary Fig. 9).WhereasPOSTN-
deficient mice maintain normal mammary gland development (Sup-
plementary Figs 10–12),MMTV-PyMT Postn2/2 breast cancers show
a dramatic decrease in the number and size of pulmonary metastases,
to less than 10%of controls, despite unaltered primary tumour size and
morphology (n5 37,P, 0.003; Fig. 3a–d and Supplementary Figs 13–
15). Metastasis formation from POSTN-deficient tumour cells is res-
cued in wild-type recipients (Supplementary Figs 16 and 17), where
expressionof POSTN is at the same level as in controls (Supplementary
Fig. 18), indicating that stromal production of POSTN determines
metastatic efficiency.
In searching for tumour-derived factors that can induce stromal
POSTN, in silico promoter analysis predicted regulation mediated
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by SMAD, NF-kB and LEF/TCF. Primary lung fibroblasts upregulate
POSTN in response to TGF-b3 and TGF-b2, but are not responsive to
BMP4,Wnt3A,Wnt5A or TNF-a (Fig. 3e, Supplementary Fig. 19 and
data not shown). Co-culture experiments revealed that tumour cells
are sufficient to trigger POSTN production (Supplementary Fig. 20).
Notably, CSCs and non-CSCs both produce high levels of TGF-b3
(Supplementary Fig. 21), and blocking the action of TGF-b3 by expres-
sion of a secreted decoy receptor22 (TGFbR2DTM; see Methods) in
tumour cells blocks POSTN expression and preventsmetastasis forma-
tion (Fig. 3f and Supplementary Fig. 22) in line with earlier results23.
Together, these experiments demonstrate that infiltrating tumour
cells need to educate the host stroma of the target organ to support
metastasis initiation.
Even small metastatic colonies are strongly diminished in POSTN-
deficient animals (SupplementaryFig. 23).Having shown thatmetastatic
colonization depends on cancer stem cells, we went on to assess a
potential role of POSTN in stem cell maintenance. Growth under
conditions of ultralow attachment has been used to study CSCs in
vitro24. Surprisingly, establishment of such cancer stem cell cultures
is not possible using POSTN-deficient tumours (Fig. 3g–j; n5 16;
compare with Supplementary Fig. 24, which shows unaltered cell
survival in standard two-dimensional culture). In wild-type tumour
spheres, POSTN is expressed by tumour-derived, stromal fibroblasts
(Supplementary Fig. 25). Adding periostin protein to the mutant
tumour cells rescues sphere formation (Fig. 3j). Conversely, a blocking
antibody targeting POSTN prevents maintenance of wild-type cancer
stem cells (Supplementary Fig. 30), but affects neither cellular survival
nor growth per se (Supplementary Figs 26 and 27). Furthermore, CSCs
fail to proliferate when co-cultured with POSTN-mutant, pulmonary
fibroblasts (Fig. 3k). In lung metastases, we observe a preferential
localization of CD901 CSCs adjacent to stromal niches (Fig. 3l),
whereas lung metastases in POSTN-deficient animals show a reduc-
tion in the size of the CSC population (Fig. 3m). Thus, POSTN is an
essential niche factor that supports CSC growth during metastatic
colonization.
To gain insight into how POSTN is related to the mechanisms that
control stem cell maintenance, we characterized the interactome of
POSTN by tandem affinity purification (TAP)-tag enrichment and
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Figure 1 | Cancer stem cells initiate metastasis. (a) Representative density
plot showing the abundance of cancer stem cells in MMTV-PyMT breast
tumours defined as CD241CD901 after gating for viable (7-AAD2) and lin2
(CD312CD452TER1192) cells (not shown). b, c, CSCs are the only cells to
form pulmonary metastases on tail vein injection. CD241CD901 CSCs and
non-CSC populations from GFP1 tumour cells freshly isolated from primary
tumours (b; 104 cells injected each) and metastases (c; 105 cells injected each)
were separately injected in recipientmice. The frequency ofCSCs (red;P, 0.01
(b), P, 0.05 (c)) ismaintained at themetastatic site (shown as pie charts; n5 6
each; errors, s.e.m.). Scale bar, 1mm.d, Time course experiments show selective
proliferation of CSCs during metastatic colonization. GFP1 tumour cells (106)
were intravenously injected into recipient mice. At the indicated time points,
the total proportion of GFP1 tumour cells in the lung (black line) and the
relative amount of the CSC population (red line) were evaluated by analysis
using fluorescence-activated cell sorting (FACS). Note the transient increase of
CSCs after oneweek (n5 4 per time point; errors, s.e.m.). e, f, CSCs are the only
cells able to initiate growth in a short-term in vivo colonization assay. e, One
week after tail vein injection of 106 GFP1 tumour cells, mice were injected with
BrdU. After 2 h, CSCs and non-CSCs were isolated by FACS and the frequency
of proliferating cells was evaluated by BrdU staining on cytospins (n5 12,
P, 0.05; errors, s.d.; representative example is shown on the right). Note the
increase of proliferation in the CSC population during the early phase of lung
colonization; by contrast, proliferation does not significantly differ between the
two populations in the primary tumour. f, GFP1 CSCs (23 105) or GFP1 non-
CSCs (43 105) were tail vein injected and analysed after two weeks. CD901/
CD241-depleted non-CSCs remained as single cells whereas CSCs were able to
initiate growth and form metastases of different sizes (S, 30–300 cells; M, 300–
3,000 cells; L,.3,000 cells). The upper panel shows a representative example of
the different metastasis colonies and the results are cumulatively quantified in
the bottom panel (n5 6). Scale bars, 20mm (e) and 250mm (f).
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tandemmass spectrometry (SupplementaryMethods), and this pointed
to binding of POSTN toWnt ligands25. Using TAP-tag pull-downs, we
confirmed interaction between POSTN and Wnt1 and Wnt3A, but
found that a known inhibitory ligand of the pathway, DKK1, does not
associate with POSTN (Fig. 4a, b and Supplementary Fig. 28). The
interaction between POSTN and Wnt ligands boosts Wnt signalling
activity as measured by LRP6 phosphorylation and reporter assays
usingWnt1, Wnt2 andWnt6 (Fig. 4c, d). TheWnt pathway is known
to control stem cell maintenance in a variety of tissues, including
mammary gland26 and tumours8,27,28. Indeed, addition of Wnt3A can
rescue in vitro stem cell expansion in the absence of POSTN (Sup-
plementary Figs 30 and 31). Furthermore, we find Wnt signalling
activity to be concentrated in the CSC population in vivo as analysed
by FACS (Fig. 4e, f). Here, we use a lentiviral reporter that allowsWnt-
inducible GFP expression and constitutive labelling of individual
reporter-containing cells by human CD2 (Supplementary Fig. 29).
Wnt signalling activity in metastases is abrogated in the absence of
POSTN (Fig. 4g; see Supplementary Fig. 29 forWnt activity in tumour
spheres). Similarly,wedetect higher levels of thegeneralWnt target gene
Axin2 in metastases in wild-type hosts than inmutant hosts (Fig. 4h, i).
Remarkably, metastasis of Wnt-driven breast cancer proves to be inde-
pendent of stromal POSTN (Fig. 4j). Thus, POSTN acts as a niche
component that can promote stem cell maintenance and metastatic
colonization by augmenting Wnt signalling (Supplementary Fig. 1).
Thus, instrumental factors that contribute to the inefficiency of the
metastatic process are the low abundance of CSCs, which are required
to initiate growth at the secondary site, and incompatibilities with
‘foreign’ niches, which necessitate education of the target organ to
resemble the primary microenvironment. Periostin is an essential
component of this CSC-supportive niche and needs to be induced in
the lung stroma by infiltrating tumour cells. Together with a recent
report that implicated tumour-cell-derived tenascin C in breast cancer
metastasis, these examples demonstrate an essential role for single
proteins of the extracellular matrix in metastatic colonization29,30.
Surprisingly, POSTN deficiency affects neither normal mammary
gland development nor tumour formation or the relative size of the
CSC population at the primary site (Supplementary Fig. 32). This may
be due to a greater complexity and redundancy in the primary niche,
such that the loss of a single factor can be tolerated. By contrast, loss
of only one important factor, such as POSTN, prevents metastatic
colonization in the presumably less supportive and less complex
secondary site. Accordingly, the early phase of metastasis can be
anticipated to be particularly sensitive to therapeutic intervention
because the dependence of cancer cells on niche signals is probably
highest in that phase. Targeting this metastatic niche promises to be
less sensitive to rapid genetic changes in cancer cells and may not only
preventmetastatic colonization butmay also interferewith the survival
of disseminated, dormant cancer cells.
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Figure 2 | POSTN is a stromal niche component that is induced on
metastasis formation. a–c, Stromal POSTN expression as detected by RNA in
situ hybridization (POSTN-expressing cells in blue) around terminal end buds,
which are enriched for mammary gland stem cells during puberty (a), tumour
cells at the primary site (b) and in pulmonary metastases (c; outlined in red).
d, Immunohistochemistry of POSTN expression in pulmonary metastases at
different stages. e–g, Immunofluorescence analysis of POSTN and fibroblast
markers in pulmonary metastases. POSTN is not expressed by PyMT tumour
cells (g), but is from aSMA1 (e) and VIM1 (f) fibroblasts. The white outline in
e defines the tumour–stroma border. h, Quantitative PCR with reverse
transcription detects POSTN expression in CD341CD312 pulmonary
fibroblasts, in CD311 endothelial cells but not in CD451 immune cells that
were isolated by FACS from lungs ofmice withmacrometastases (n5 3; errors,
s.d.). i, j, Immunohistochemistry of POSTN expression in auxiliary lymph
nodes of human breast cancer patients with metastasis-free N0 disease (j) or
metastatic disease (i). A total of 17 of 23 lymph node metastases were positive
for POSTN expression. Scale bars: 20mm (a) and 2.5mm (a, inset); 50mm
(b; same scale in c) and 10mm (b, inset); 50mm (d); 20mm (e–g); 200mm (i, j).
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Figure 3 | POSTN is required for metastatic
colonization by affecting CSC maintenance.
a, b, Primary tumour size (a) and number of
spontaneously formed macrometastases (b) in
control andPostn2/2mice (n5 37). c, d, HE section
of spontaneous, pulmonary metastases in control
(c) and POSTN-mutant (d) animals. e–f, TGF-b3
induces POSTN expression in lung stromal cells.
e, TGF-b3 was added to lung stromal cells to test its
ability to induce POSTN expression. RNA
expression by quantitative PCR and protein
expression by western blot analysis (inset) were
measured at the indicated concentrations. f, Blocking
of TGF-b3 abrogates metastasis formation. Cancer
cells were infected either with a control virus or with
a virus expressing secreted, dominant negative
TGFbR2DTM and separately intravenously injected
into recipient mice. Metastasis formation was
evaluated 6 weeks after injection (n5 12; errors,
s.d.). g, Frequency ofmammosphere formation from
primary tumours. WT, wild type. h, Representative
picture of control tumourmammospheres. i, Loss of
CSCs in secondary mammosphere assays from
Postn2/2 tumours. j, Sphere formation by Postn2/2
tumour cells can be rescued by addition of
50ngml21 of periostin to primary cultures. Control
tumour cells produce 13.36 2.5 spheres per 30,000
cells.Quantification is shown in thehistogramon the
right (n5 4; errors, s.d.). k, Only stromal cells
isolated from wild-type lungs are able to support
CSC colony formation in vitro. CSCs were sorted by
FACSandseededon lung stromal cells isolated either
fromwild-type or Postn2/2 mice. Colony formation
was evaluated after two weeks (n5 3; errors, s.d.).
l, Immunofluorescence analysis shows that
GFP1CD901 CSCs (white arrow heads) are
concentrated in areas with immediate contact to the
stroma.m, Reduced frequency of CD241CD901
CSCs in rare pulmonary metastases in POSTN-
deficient mice (n5 12; errors, s.d.). Scale bars:
500mm (c, d); 50mm (h–j); 5mm (l).
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Figure 4 | POSTN promotes stem cell maintenance and metastasis
formation by augmenting Wnt signalling. a, Interaction of TAP-tagged
POSTN and Wnt3A and Wnt1 as determined by pull down and western
blotting. b, Interaction of TAP-tagged POSTN and DKK1 as determined by
pull down and western blotting. Note the absence of interaction between
POSTN and DKK1. c, LRP6 phosphorylation (pLRP) increases on POSTN
expression. d, Wnt reporter activity in response to Wnt1, Wnt2 or Wnt6 is
stimulated by POSTN (n5 3; errors, s.d.). e, f, In vivo Wnt reporter assay.
Tumour cells were infected with a lentivirus containing both an artificial Wnt-
responsive promoter driving GFP expression and a constitutive promoter
expressing human CD2 (Supplementary Fig. 29). Cells were analysed by FACS
considering only human-CD21, reporter-containing cells. CD901CD241
CSCs and non-CSCs were scored forWnt reporter activity as GFP1. The signal
concentrates in CSCs in both primary tumours (e) and pulmonary metastases
(f) (n5 3; errors, s.e.m.). g, CD901CD241 wild-type CSCs containing a Wnt
reporter (human CD21) show signalling activity (GFP1) only when seeded in
wild-type as opposed to Postn2/2 lungs (n5 3; errors, s.e.m.).
h, i, Immunofluorescence staining of AXIN2 in control (h) and POSTN-
deficient (i) lungmetastases (outlined in white). Note the absence of staining in
POSTN2 lung metastases. Scale bar, 10mm. j, MMTV-Wnt1 tumour cells can
form pulmonarymetastases in the absence of POSTN expression in the stroma.
Tumour cells were orthotopically transplanted into mammary glands of wild-
type or POSTN-deficient recipients and analysed after ten weeks for
spontaneous lung metastasis (n5 5 each; errors, s.d.).
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METHODS SUMMARY
Details on the mouse models used and the generation of the Postn gene ablation
can be found in Supplementary Information. Tumours derived from MMTV-
PyMT mice were collected and cells were isolated and directly stained for FACS
analysis or sorting using antibodies against CD31, CD45, TER119 (LY76), CD90,
CD24 andCD49f (ITGA6). FACS-isolated tumour cells were directly transplanted
into recipient mice.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Mouse work. The design of the POSTN targeting vector is shown in
Supplementary Fig. 10. E14.1 129/Ola ES cells were used for targeting and were
injected into C57Bl6 blastocysts. The POSTNmutant allele was then backcrossed
onto the FVB background for at least eight generations. The MMTV-PyMT31,
MMTV-Wnt132 and the ACT–GFP33 mouse strains have been described previ-
ously. All used strains were backcrossed onto FVB for ten generations except for
the Nude allele, which was used on a NMRI background. For tumour cell trans-
plantations,Nude orRag12/2micewere usedwhen tumour cells expressedGFPor
had been modified by lentiviral vectors. In general, we did not observe major
differences in these different strains with respect to cancer stem cell phenotype,
tumour take rate or metastasis number, except for an overall faster growth in
Rag12/2 versus Nude versus wild type. For tail vein injections, tumour cells were
resuspended in 100ml of PBS. For orthotopic transplantations, tumour cells were
resuspended in 50ml growth-factor-reduced matrigel (BD Biosciences) and trans-
planted into a small pocket within the fourth mammary fat pad. All animal
procedures were performed in accordance with the Swiss legislation on animal
experimentation.
Antibodies. We used TER119, CD24, CD29, CD34, CD45 and CD90.1
(eBioscience); CD31 and GFP (Invitrogen); Cytokeratin 8, POSTN, AXIN2 and
Wnt1 (Abcam); POSTN (Adipogen); Cytokeratin 14 (Covance); GATA-3 and
PyMT (Santa Cruz Biotechnology); aSMA (Sigma); VIM (Lifespan Biosciences);
and BrdU (BD Pharmingen and ImmunologicalsDirect). The antibody against
human CD2was a kind gift by ProfessorWerner Held (Ludwig Center for Cancer
Research, Lausanne).
Tumour and metastasis evaluation. For the quantification of spontaneous
micrometastasis, lungs were completely sectioned and HE stained, and the size
and the number of metastatic nodules were analysed by microscopy.
Quantification of lungmetastases derived fromGFP1 tumour cells was performed
by fluorescentmicroscopy (LeicaM205 FA stereomicroscope) or by FACS analysis
of cell preparations from total lungs. All statistical evaluationused ahomoscedastic
Student’s t-test with a two-tailed distribution.
For expression of a secretedTGFb decoy receptor (TGFbR2DTM), tumour cells
were transduced with lentiviral vectors expressing the extracellular domain
(amino acids 1–185) of murine TGFbR2 (NM_009371.3) under the control of a
murine phosphoglycerate kinase (PGK) promoter, and metastases were scored as
described above following tail vein injection of transduced tumour cells.
Tumour cell isolation. Tumours or lungs containing pulmonarymetastases were
minced with a razor blade and digested with a mixture of DNase and Liberase
(Roche Diagnostics). On enzymatic digestion, samples were passed through a
100-mm filter and washed once in growth medium (DMEM/F12 with 2% FBS,
20 ngml21 EGF, 10mgml21 insulin; Invitrogen) and twice in PBS. Cells were then
directly used for FACS staining and analysed in a Cyan ADP flow cytometer
(Beckman Coulter) or sorted with a custom-built FACSAria II (Beckton
Dickinson). For tail vein injection, cells were plated overnight on collagen. In
the experiments evaluating the metastasis initiation potential of CSCs versus
non-CSCs, wewere able to prepare and inject higher cell numbers frommetastases
than from primary tumours, where larger necrotic areas limit the obtainable cell
amounts. In both settings, only CSCs were able to give rise to pulmonary
metastases, but this experimental setting is unsuitable for a direct comparison of
the metastatic potential of CSCs isolated from primary tumours with that of those
isolated from metastases. In the extravasation experiments, we performed several
pilot experiments perfusing the lungs before dissection to distinguish cells trapped
inside capillaries from those that successfully extravasated. Perfusion was done
with Ringer’s buffer through the right ventricle for 5–10min.
Tumour mammosphere cultures. Sphere cultures were established from total
tumour cell preparations. After dissociation, tumour cells were plated on collagen
overnight, trypsinized andplated in 100ml of spheremedia (DMEM/F12with B27,
20 ngml21 EGF, 20 ngml21 FGF and 4mgml21 heparin) into 96-well, low-attach-
ment plates (Constar) at a concentration of (1–3)3 104 cells per well. For the anti-
POSTN blocking antibody assay, half of the culture medium was replaced by
hybridoma supernatant. Secondarymammosphere culture was performed by col-
lecting the spheres through gentle centrifugation (130g) followed by enzymatic
(10min in 0.05% trypsin-EDTAat 37 uC) andmechanical dissociation using a 25G
needle. Immunostainingswere performed aswholemounts of PFA-fixed and0.1%
Triton-X100-permeabilized spheres and were analysed by confocal microscopy.
Identification of POSTN as a niche-expressed factor. To identify niche-
expressed factors, we performed microarray RNA profiling studies where we
analysed laser-capture microdissected material from normal stem cells together
with their adjacent stroma. This was compared with laser-capture microdissected
material isolated fromdifferentiated cells together with their adjacent stroma from
the same tissue (data not shown). Skin and intestine contain stem cells in mor-
phologically distinct structures (the bulge in the skin, the crypt in the intestine).On
the basis of these profiles (accessible through GEO GSE31730 and 8818),
we evaluated potential niche localization of candidate genes by RNA in situ
hybridization and immunofluorescence analysis (Fig. 2a, Supplementary Fig. 7
and data not shown). Moreover, we profiled the candidate genes by quantitative
PCR with reverse transcription and performed RNA in situ hybridization in other
tissues, in tumours and in metastases (data not shown). This identified POSTN as
a stromal marker in primary murine breast cancer and its metastases (Fig. 2).
Immunodetection and in situ hybridization. Immunostaining was performed
on 7-mm OCT- or gelatin-embedded (to maintain GFP signals) frozen sections
permeabilized with 0.1% Triton-X100 or on 5-mm paraffin sections using antigen
retrieval for 20min in boiling, 10mM citric acid, pH 6.0. For BrdU immunostain-
ing, an additional incubation period of 10min in 2N HCl was performed. For
immunohistochemistry, endogenous peroxidaseswere blocked by incubationwith
0.6%H2O2 inmethanol. After incubationwith the indicated antibodies, secondary
fluorescently labelled antibodies Alexa Fluor 488, 567 and 647 (Molecular Probes,
Invitrogen) or HRP-conjugated secondary antibodies were used to reveal the
primary antibodies. For immunohistochemistry, Dako Envision1 was used
together with diaminobenzidine tablets (Sigma) to detect HRP. Fluorescent
images were made with an automated upright microscope system (DM5500,
Leica) or an LSM700 upright or inverted confocal microscope (Zeiss). Light
images were made with an AX70 widefield microscope (Olympus). Figures were
generatedwith PHOTOSHOP (Adobe Systems) andCYTOSKETCH (CytoCode).
In situ hybridizations were performed on paraffin sections permeabilized by
proteinase K digestion using DIG-labelled (Roche), antisense transcripts of the
mouse POSTN complementary DNA. After hybridization, sectionwere washed in
50% formamide, 35 SSC (0.75M NaCl, 85mM sodium citrate, pH 7.0) and 0.1%
Tween at 70 uC, and non-specifically bound probe was digested by RnaseA treat-
ment, followed by extensive washing in 50% formamide,32 SSC and 0.1% Tween
at 65 uC. The DIG label was detected by an anti-DIG Fab (Roche) coupled to
alkaline phosphatase using FAST NBT/BCIP (Sigma).
Western blot. Protein was extracted with complete RIPA buffer, separated by
electrophoresis, transferred to PVDF membranes, blocked with 5% dry milk or
BSA and incubated overnight with primary antibodies. Immunoreactive bands
were visualized using HRP-conjugated secondary antibodies (Promega) and the
detection reagent SuperSignal West Cheminoluminiscent Substrate (Thermo
Scientific).
Real-time RT–PCR. RNA was prepared using a miniRNA or microRNA kit
(Qiagen) fromFACS-isolated primary cells. ComplementaryDNAswere generated
using oligo-T priming and quantitative PCR was performed in a LightCycler
(Roche) or a StepOnePlus thermocycler (Applied Biosystems) using the Power
SYBR green PCRMasterMix (Applied Biosystems) and the primers aatgctgccctggc
tatatg and gcatgacccttttccttcaa (POSTN); agcgcagacacaacccatag and gggttctgccca
catagtacaag (TGF-b3); and caagctcatttcctggtatgacaat and gttgggatagggcctctcttg
(GAPDH).
Periostinmonoclonal antibody production. In collaborationwith Adipogen, we
injected Postn2/2 mice with purified human POSTN protein. Hybridomas were
generated and tested for antibody production by ELISA. Antibodies were selected
for their ability to recognize POSTNand for their ability to block tumourmammo-
sphere formation in vitro.
Periostin interactome and pull-downs. Freshly isolated tumour cells were grown
under mammosphere conditions in the presence of purified, polyHis-tagged and
streptavidinbinding peptide (SBP)-taggedPOSTNprotein (Supplementary Fig. 28)
for 72h. Then proteins were crosslinked by 1mM DTSSP (Pierce) for 10min and
solubilized by DDM and SDS (Anatrace). Protein purification was achieved by two
successive affinity purification steps using the SBP and the polyHis tags and elution
by biotin and imidazole, respectively. After elution, the crosslink was released by
DTT treatment, the resulting protein mixture was trypsin-digested and peptides
were identified by one-dimensional nano-liquid chromatography tandem mass
spectrometry. Among the POSTN-attached proteins, we found Wnt6 to be a
potential interactor. Because these experiments involved crosslinkers, we consider
these results to be preliminary unless confirmed by independent experiments.
For Wnt6, an interaction with POSTN could not be validated owing to a lack of
Wnt6 antibodies and a suitable expression system for Wnt6. Nevertheless, this
preliminary finding prompted us to test directly for interactions of POSTN with
other Wnt ligands where the necessary tools are available. For these pull-downs,
cDNAs encoding Wnt1, HA-tagged Wnt3A, DKK1 and SBP/His-tagged POSTN
(Supplementary Fig. 28) or SBP/His-tagged mouse immunoglobulin-G heavy
chain (as a control) were transfected separately into 293T cells. Cells secreting
POSTNor immunoglobulin-G and cells producingWnt or DKKweremixed after
onedayandcollected for pull-downs after three additional days.Without the useof
crosslinkers, POSTN-interacting proteins were enriched by the SBP/His tag as
described above using NP40 as detergent. Western blot was performed for iden-
tification of the pulled-down proteins.
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Wnt reporter activity. HEK293T cells were transduced with a lentiviral vector
containing a LEF/TCF-responsive luciferase reporter consisting of a minimal
promoter and 20 copies of the LEF/TCF consensus site or a control construct in
which the LEF/TCF sites had been mutated34. These stableWnt reporter cell lines
were then transiently transfected with a POSTN expression vector before these
cells were mixed with transiently transfected HEK293T or COS7 cells (the latter
forWnt6 expression) producingWnt1,Wnt2 orWnt6, respectively. Themedia on
these co-cultures ofWnt reporter andWnt producer cells were replaced after 24 h
to remove soluble Wnt ligands. After 48 h of co-culture, luciferase activity in cell
extracts was measured with a kit from Promega.
For in vivo reporter assays, we generated a lentiviral vector containing the same
transcription factor sites and minimal promoter as described above driving GFP
expression. In addition, this vector contained a ubiquitous PGK promoter driving
expression of a truncated humanCD2cDNA that allows identificationof reporter-
containing cells by FACS (Supplementary Fig. 29). Lentiviruses were generated in
293T cells using third-generation lentivirus packaging vectors, and virus particles
were concentrated by ultracentrifugation. Freshly isolated tumour cells were
infected with lentiviruses overnight, enriched by anti-CD2 MACS (Miltenyi) for
cells carrying the reporter construct and orthotopically transplanted for tumour
formation and spontaneous metastasis. Wnt signalling activity in cells of primary
tumours or spontaneouspulmonarymetastaseswas quantifiedbyFACS analysis by
measuringGFP1 cells after gating for human-CD21 cells. Similarly, human-CD21
tumour cells were used for tumour mammosphere cultures to measure Wnt path-
way activity in the presence or absence of the POSTN blocking antibody.
Isolation of lung stromal cells. Lungs were minced with a razor blade and
digestedwith amixture ofDNase andLiberase (RocheDiagnostics). On enzymatic
digestion, sampleswere passed through a 100-mmfilter andwashedonce in growth
medium (DMEM/F12 with 2% FBS, 20 ngml21 EGF and 10mml21 insulin;
Invitrogen) and twice inPBS.Cellswere plated ontoplates pretreatedwith collagen
and allowed to attach for three days. Themediumwas then changed to serum-free
medium and tumour cells or soluble factors were added to test POSTN induction.
POSTN expression was evaluated by western blot, PCRwith reverse transcription
or immunofluorescence analysis.
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